Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors

NCT06024174 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT06024174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06024174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Terminated
Start date
November 9, 2023
Completion date
May 13, 2024
Enrollment
5 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors